T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy

Cancer Research

Volumn 61, Issue 5, 2001, Pages 2062-2070

  Kirk, Christopher J ^a   Hartigan O’Connor, Dennis ^a   Nickoloff, Brian J ^c   Chamberlain, Jeffrey S ^a   Giedlin, Martin ^d   Aukerman, Lea ^d   Mulé, James J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; RECOMBINANT CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CELL LYSATE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; FEMALE; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOID TISSUE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHEMOKINES, CC; DENDRITIC CELLS; FEMALE; GENE THERAPY; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 0035266293     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. A new era for cancer immunotherapy based on the genes that encode cancer antigens
2. The makings of a tumor rejection antigen
3. Cancer vaccines
4. Dendritic cells and the control of immunity
5. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
6. Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures
7. Dendritic cell vaccines for cancer immunotherapy
8. Dendritic cells: At the clinical crossroads
9. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells
10. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
11. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Gene-modified dendritic cells for use in tumor vaccines
14. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
15. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity
16. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity
17. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
18. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
19. Intratumoral administration of adenoviral interleukin-7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication
20. The role of chemokine receptors in primary, effector, and memory immune responses
21. Chemokines and leukocyte traffic
22. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7
23. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7
24. Identification and characterization of a novel β chemokine containing six conserved cysteines
25. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13
26. Cutting edge: Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
27. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7
28. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 β are potent chemoattractants for in vitro- and in vivo-derived dendritic cells
29. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes
30. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs
31. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization
32. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
33. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
34. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
35. Biological behavior of malignant melanoma cells correlated to their survival in vivo
36. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung
37. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
38. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
39. Selective extraction of polyoma DNA from infected mouse cell cultures
40. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
41. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1
42. A simplified system for generating recombinant adenoviruses
43. Adenovirus vector
44. Factors that influence stability of recombinant adenoviral preparations for human gene therapy
45. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
46. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
47. Migration of human dendritic cells after injection in patients with metastatic malignancies
48. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
49. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
50. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
51. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
52. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
53. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
54. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
55. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
56. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3
57. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
58. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo
59. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: Perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
60. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy
61. The CC chemokine CK β-11/MIP-3 β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
62. Combined chemokine and cytokine gene transfer enhances antitumor immunity
63. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
64. Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells
65. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
66. Developments in gene therapy for muscular dystrophy
67. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
68. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene